Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: Evaluation of physicochemical, transport and antithrombic properties

Journal of Peptide Research

Volumn 61, Issue 6, 2003, Pages 331-342

  He, H T ^a   Xu, C R ^a   Song, X ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

(Acyloxy)alkoxy linker; Antithrombic activity; Cellular membrane permeation; Cyclic prodrug; RGD peptidomimetic

Indexed keywords

CARBENE; ESTERASE; PRODRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CYCLIZATION; DRUG ACTIVITY; DRUG SYNTHESIS; DRUG TRANSPORT; ENZYME ISOLATION; ENZYME STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRODYNAMICS; HYDROPHOBICITY; MOLECULAR SIZE; MOLECULAR STABILITY; PH; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; BIOMIMETIC MATERIALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DRUG STABILITY; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PRODRUGS;

EID: 0038147438     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3011.2003.00062.x     Document Type: Article

References (32)

1. Nicholson, N.S., Abood, N.A., Panzer-Knodle, S.G., Frederick, L.G., Page, J.D., Salyers, A.K., Suleymanov, O.D., Szalony, J.A., Taite, B.B. & Anders, R.J. (2001) Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med. Res. Rev. 21, 211-226.
2. Scarborough, R.M. & Gretler, D.D. (2000) Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombic agents. J. Med. Chem. 43, 3453-3473.
3. Zabloeki, J.A., Rico, J.G., Garland, R.B., Rogers, T.E., Williams, K., Schretzman, L.A., Rao, S.A., Bovy, P.R., Tjoeng, F.S., Lindmark, R.J. & et al. (1995) Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J. Med. Chem. 38, 2378-2394.
4. Tsuchiya, Y., Sawada, S., Tsukada, K. & Saiki, I. (2002) A new pseudo-peptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int. J. Oncol. 20, 319-324.
5. Buerkle, M.A., Pahernik, S.A., Sutter, A., Jonczyk, A., Messmer, K. & Dellian, M. (2002) Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br. J. Cancer 86, 788-795.
6. Ruoslahti, E. (1991) Integrins as receptors for extracellular matrix, In Cell Biology of Extracellular Matrix (Hay, E.D. ed.), Plenum Press, New York, NY.
7. 3. J. Med. Chem. 37, 1-8.
8. Batchelor, W.B., Tolleson, T.R., Huang, Y., Larsen, R.L., Mantell, R.M., Dillard, P., Davidian, M., Zhang, D., Cantor, W.J., Sketch, M.H., Jr., Ohman, E.M., Zidar, J.P., Gretler, D., DiBattiste, P.M., Teheng, J.E., Califf, R.M. & Harrington, R.A. (2002) Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 106, 1470-1476.
9. Song, X., He, H.T. & Siahaan, T.J. (2002) Synthesis of cyclic prodrugs of Aggrastat and its analogue with a modified phenylpropionic acid linker. Org. Lett. 4, 549-552.
10. Song, X., Xu, C.R., He, H.T. & Siahaan, T.J. (2002) Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation. Bioorg. Chem. 30, 285-301.
11. Wang, W., Borchardt, R.T. & Wang, B. (2000) Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists. Curr. Med. Chem. 7, 437-453.
12. Wang, B., Wang, W., Camenisch, G.P., Elmo, J., Zhang, H. & Borchardt, R.T. (1999) Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability. Chem. Pharm. Bull. (Tokyo) 47, 90-95.
13. Wang, W., Camenisch, G., Sane, D.C., Zhang, H., Hugger, E., Wheeler, G.L., Borchardt, R.T. & Wang, B. (2000) A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics. J. Control. Release 65, 245-251.
14. Bak, A., Siahaan, T.J., Gudmundsson, O.S., Gangwar, S., Friis, G.J. & Borchardt, R.T. (1999) Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid pentapeptides using an (acyloxy)alkoxy linker. J. Pept. Res. 53, 393-402.
15. Bak, A., Gudmundsson, O.S., Friis, G.J., Siahaan, T.J. & Borchardt, R.T. (1999) Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm. Res. 16, 24-29.
16. Wang, B., Nimkar, K, Wang, W., Zhang, H., Shan, D., Gudmundsson, O.S., Gangwar, S., Siahaan, T.J. & Borchardt, R.T. (1999) Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers. J. Pept. Res. 53, 370-382.
17. Ouyang, H., Borchardt, R.T., Vander Velde, D.G. & Siahaan, T.J. (2002) Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion. J. Pept. Res. 59, 183-195.
18. Ouyang, H., Tang, F., Siahaan, T.J. & Borchardt, R.T. (2002) A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics. Pharm. Res. 19, 794-801.
19. Pauletti, G.M., Gangwar, S., Knipp, G.T., Nerurkar, M.M., Okumu, F.W., Tamura, K., Siahaan, T.J. & Borchardt, R.T. (1996) Structural requirements for intestinal absorption of peptide drugs. J. Control. Rel. 41, 3-17.
20. Gudmundsson, O.S., Nimkar, K., Gangwar, S., Siahaan, T.J. & Borchardt, R.T. (1999) Phenylpropionic acid-based cyclic products of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation. Pharm. Res. 16, 16-23.
21. Pauletti, G.M., Gangwar, S., Siahaan, T.J., Aube, J. & Borchardt, R.T. (1997) Improvement of oral peptide bioavailability: peptide mimetics and prodrug strategies. Adv Drug Del. Rev. 27, 235-256.
22. Pauletti, G.M., Gangwar, S., Okumu, F.W., Siahaan, T.J., Stella, V.J. & Borchardt, R.T. (1996) Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13, 1615-1623.
23. Gangwar, S., Pauletti, G.M., Siahaan, T.J., Stella, V.J. & Borchardt, R.T. (1997) Synthesis of a novel esterase-sensitive cyclic prodrug of a hexapeptide using an (acyloxy)alkoxy promoiety. J. Org. Chem. 62, 1356-1362.
24. Jois, S.D.S., Tambunan, U.S.F., Chakrabarti, S. & Siahaan, T.J. (1996) Solution structure of a cyclic RGD peptide that inhibits platelet aggregation. J. Biomol. Struc. Dyn. 14, 1-12.
25. Gudmundsson, O.S., Velde, D.G.V., Jois, S.D.S., Bak, A., Siahaan, T.J. & Borchardt, R.T. (1999) The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs opioid peptides on their membrane permeability. J. Pept. Res. 53, 403-413.
26. Liu, H., Ong, S., Glunz, L. & Pidgeon, C. (1995) Predicting drug-membrane interactions by HPLC: structural requirements of chromatographic surfaces. Anal. Chem. 67, 3550-3557.
27. Bogdanowich-Knipp, S.J., Chakrabarti, S., Williams, T.D., Dillman, R.K. & Siahaan, T.J. (1999) Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res. 53, 530-541.
28. Gudmundsson, O.S., Jois, S.D.S., Velde, D.G.V., Siahaan, T.J., Wang, B. & Borchardt, R.T. (1999) The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic products of opioid peptides. J. Pept. Res. 53, 383-392.
29. Tang, F. & Borchardt, R.T. (2002) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm. Res. 19, 787-793.
30. Tang, F. & Borchardt, R.T. (2002) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE. Pharm. Res. 19, 780-786.
31. Hartman, G.D., Egbertson, M.S., Halczenko, W., Laswell, W.L., Duggan, M.E., Smith, R.L., Naylor, A.M., Manno, P.D., Lynch, R.J., Zhang, G., Chang, T.-C. & Gould, R.J. (1992) Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640-4642.
32. Egbertson, M.S., Chang, T.-C., Duggan, M.E., Gould, R.J., Halczenko, W., Hartman, G.D., Laswell, W.L., Lynch, Jr., J.J., Manno, P.D., Naylor, A.M., Prugh, J.D., Tamjit, D.R., Sitko, G.R., Smith, R.S., Turchi, L.M. & Zhang, G. (1994) Non-peptide fibrinogen receptor antagonist. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. 37, 2537-2551.